salvinorin a has been researched along with 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride in 1 studies
| Studies (salvinorin a) | Trials (salvinorin a) | Recent Studies (post-2010) (salvinorin a) | Studies (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride) | Trials (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride) | Recent Studies (post-2010) (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride) |
|---|---|---|---|---|---|
| 247 | 7 | 128 | 113 | 2 | 41 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rotella, D | 1 |
1 other study(ies) available for salvinorin a and 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride
| Article | Year |
|---|---|
American Chemical Society--233rd National Meeting. CNS, cancer and cardiovascular targets. 25-29 March 2007, Chicago, IL, USA.
Topics: Animals; Binding Sites; Cardiovascular Diseases; CD11b Antigen; CD18 Antigens; Diterpenes; Diterpenes, Clerodane; Drug Delivery Systems; Drug Design; Drugs, Investigational; Humans; Integrin alpha4beta1; Lobeline; Mice; Neoplasms; Pain; Piperazines; Quantitative Structure-Activity Relationship; Receptor, PAR-1; Receptors, G-Protein-Coupled; Receptors, Opioid, kappa; Sodium Channel Blockers; Vesicular Monoamine Transport Proteins | 2007 |